Drug Trial Radar · NCT06864988
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Mar 3, 2025
Primary completion
Jun 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- 4D Molecular TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Conditions
- Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions
4D-150 IVT (3E10 vg/eye)Biological
If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1
EYLEA® (aflibercept) Injection 2 mg (0.05mL)Biological
Eylea (aflibercept) will be administered at applicable visits
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in BCVA ETDRS letter score at Week 52Time frame: 52 Weeks
Locations
94 sites in 2 countries. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center
Phoenix, Arizona
Retinal Research Institute, LLC
Scottsdale, Arizona
Retina Partners of Northwest Arkansas
Springdale, Arkansas
California Retina Consultants
Bakersfield, California
Retina Vitreous Associates Medical Group
Beverly Hills, California
The Retina Partners
Encino, California
Retina Associates of Southern California
Huntington Beach, California
Northern California Retina Vitreous Associates
Mountain View, California
Retina Consultants of San Diego
Poway, California
Kaiser Permanente-Riverside Medical Center
Riverside, California
Retinal Consultants Medical Group Inc
Sacramento, California
Retinal Consultants Medical Group Inc
Sacramento, California
Orange County Retina Medical Group
Santa Ana, California
California Retina Consultants - Santa Barbara
Santa Barbara, California
Bay Area Retina Associates
Walnut Creek, California
University of Colorado, Denver
Aurora, Colorado
Retina Consultants of Southern Colorado
Colorado Springs, Colorado
RSC Research, LLC
Denver, Colorado
Connecticut Eye Consultants
Danbury, Connecticut
Retina Group of Florida
Fort Lauderdale, Florida
Vitreo Retinal Associates
Gainesville, Florida
Florida Retina Institute - Jacksonville
Jacksonville, Florida
Florida Retina Consultants
Lakeland, Florida
Florida Retina Institute
Orlando, Florida
Retina Specialty Institute
Pensacola, Florida
Retina Associates of Sarasota
Sarasota, Florida
Retina Vitreous Associates of Florida
St. Petersburg, Florida
East Florida Eye Institute
Stuart, Florida
Southeast Retina Center
Augusta, Georgia
Georgia Retina PC
Marietta, Georgia
Retina Consultants of Hawaii
‘Aiea, Hawaii
University of Chicago
Chicago, Illinois
Retina Associates - Elmhurst
Elmhurst, Illinois
University Retina and Macula Associates, PC
Lemont, Illinois
Illinois Retina Associates
Oak Park, Illinois
Springfield Clinic
Springfield, Illinois
Midwest Eye Institute
Carmel, Indiana
Retina Associates of Kentucky
Lexington, Kentucky
Maine Eye Center
Portland, Maine
Retina Group of Washington, Chevy Chase
Chevy Chase, Maryland
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.